GlobeNewsWire
01 Sept 2026, 10:30 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
NHS England is expanding the Barts Health pharmacy cholesterol testing programme, powered by Avricore's HealthTab platform, to approximately 100 pharmacies nationwide. — Transitioning from a regional pilot to a national NHS initiative significantly increases the addressable market and validates the commercial viability of the product.
+0.80A pilot study of 2,493 patients showed that 19% were identified as high risk for heart attack or stroke, with at least 88 patients initiating statin therapy. — Provides concrete clinical efficacy data that supports the necessity of the service and justifies further government funding/adoption.
+0.50The first national phase of the rollout is scheduled to run from this fall through spring 2027. — Establishes a clear timeline for revenue realization and operational scaling for the company.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company's HealthTab platform is being expanded nationally across England by NHS England.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
24m ago
